Takeda Presents Phase 2/3 Results for TAK-881 in Maastricht

Takeda presented detailed results from the pivotal Phase 2/3 IgGNITE clinical trial for TAK-881 at the 22nd Biennial Meeting of the European Society for Immunodeficiencies in Maastricht. The trial met its primary endpoint, demonstrating pharmacokinetic comparability between TAK-881 and HYQVIA®. Secondary analyses showed that TAK-881 could potentially shorten infusion times and require 50% less volume compared to HYQVIA, while maintaining once-monthly dosing for patients aged 16 years and older.

If approved, TAK-881 could become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease administered up to once-monthly. The results suggest a potential shift in treatment protocols and supply for this specialized market.